QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns

QuidelOrtho Corporation QDEL sharply lowered its 2026 outlook after second-quarter results as China purchasing weakened and management adopted more conservative respiratory-season assumptions. The reset reduces near-term earnings visibility and raises the importance of cash conversion.

Core businesses are still growing, but the lower revenue, EBITDA and earnings ranges show that those gains are not enough to offset the company’s largest near-term pressures. The revised outlook also makes balance-sheet improvement harder to achieve.

QDEL’s Guidance Reset Is Material

QuidelOrtho now expects 2026 revenues of $2.52-$2.60 billion, down from its prior $2.70-$2.75 billion range. The cut reflects weaker demand expectations in China and a softer respiratory environment.

Adjusted EBITDA guidance fell to $540-$560 million from $615-$630 million, while adjusted earnings expectations dropped to 65-90 cents per share from $1.80-$2.00. The scale of the reductions points to a materially weaker earnings trajectory for the remainder of the year.

China Pricing Changes Hit QDEL’s Demand Outlook

The second draft of China’s in-vitro diagnostics pricing guidelines changed the market backdrop. Management said the draft broadened product coverage, removed methodology and use-case differentiation and expanded the pilot from three provinces to six.

After quarter-end, customers reduced inventories more quickly and significantly than QuidelOrtho had anticipated. Final guidelines and implementation timing remain uncertain, and management expects China challenges to persist through the remainder of 2026.

Image Source: Zacks Investment Research

QDEL Turns More Cautious on Respiratory Demand

QuidelOrtho has shifted away from using an average respiratory season as its planning baseline. It now assumes the second-half respiratory environment will be closer to the lower end of historical seasons.

Management cited U.S. positivity rates that were significantly below year-ago levels and Southern Hemisphere data that suggested either a later or softer season. That more conservative stance reduces the earnings recovery previously expected from seasonal testing demand.

Core QDEL Businesses Provide a Partial Offset

Second-quarter Labs revenues rose 3.6% year over year, Immunohematology increased 1.4% and Point of Care advanced 16.3% on a reported basis. Excluding China, total revenues grew 6% at constant currency, showing that the broader portfolio retains pockets of resilience.

The competitive diagnostics backdrop remains active. Abbott Laboratories ABT reported $3.1 billion in second-quarter 2026 Diagnostics sales, while Danaher Corporation DHR reported 7% year-over-year Diagnostics revenue growth. QDEL’s core growth is encouraging, but it was not sufficient to prevent the full-year outlook reduction.

QDEL’s Cash Conversion Adds to the Consequences

Operating activities used $143.6 million of cash during the first six months of 2026 compared with cash generation a year earlier. QuidelOrtho also withdrew its free cash flow guidance because of uncertainty tied to China, respiratory demand and working-capital effects.

Total debt increased to $2.89 billion at quarter-end from $2.69 billion at the end of the first quarter. With earnings visibility reduced, improving cash conversion becomes more important to the company’s efforts to lower leverage and strengthen the balance sheet.

QDEL’s Bearish Signal Reflects the Outlook Reset

The guidance reduction leaves QuidelOrtho facing a difficult near-term setup. Core growth provides some support, but China uncertainty, respiratory volatility, cash use and elevated debt keep the risk-reward balance unfavorable.

The stock currently carries a Zacks Rank #5 (Strong Sell). QDEL has a Value Score of B, which points to relatively favorable value characteristics, but its Growth Score of F and Momentum Score of F indicate weak growth and momentum traits. Its VGM Score of D further signals an unfavorable combined profile. Because Style Scores complement the Zacks Rank, this mix reinforces a cautious view even though the value reading is stronger than the other style factors.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research